about
Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling
P50
description
researcher ORCID ID = 0000-0001-9406-0386
@en
wetenschapper
@nl
name
Chalada Suebsuwong
@ast
Chalada Suebsuwong
@en
Chalada Suebsuwong
@es
Chalada Suebsuwong
@nl
type
label
Chalada Suebsuwong
@ast
Chalada Suebsuwong
@en
Chalada Suebsuwong
@es
Chalada Suebsuwong
@nl
prefLabel
Chalada Suebsuwong
@ast
Chalada Suebsuwong
@en
Chalada Suebsuwong
@es
Chalada Suebsuwong
@nl
P1153
56465964700
P31
P496
0000-0001-9406-0386